Author of

• 28315

  +

  11 - Surgically Resectable (ID 11)

  • Event: TTLC 2019
  • Type: General Session
  • Track:
  • Presentations: 1
  • Moderators:Nasser Altorki, Raymond Osarogiagbon
  • Coordinates: 2/22/2019, 08:00 - 09:05, Starlight Ballroom

  • 28431

    +

    Neoadjuvant Atezolizumab (LCMC3) and Pembrolizumab (ID 11.02)

    08:00 - 09:05  |  Author(s): Jay Lee
    • Abstract
    • Slides

    Abstract not provided

    Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.